New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eikon Therapeutics, Inc. (EIKN) vs Prelude Therapeutics Incorporated (PRLD)

Eikon Therapeutics, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Eikon Therapeutics, Inc. and Prelude Therapeutics Incorporated are of similar size ($260.5M and $257.9M). Across the 8 metrics below, Prelude Therapeutics Incorporated leads on 5 and Eikon Therapeutics, Inc. on 3.

Valuation

Metric EIKN PRLD Biotechnology median
P/E n/m n/m 8.49
P/S — 15.44 8.56
P/B 0.67 2.68 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.61 n/m 0.69
EV/Sales — 8.95 8.00
Earnings yield (670.53%) (18.32%) (35.81%)
Free cash flow yield (103.42%) (8.40%) (25.41%)

Profitability

Metric EIKN PRLD Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (283.92%) 0.00%
Net margin — (247.12%) 0.00%
Free cash flow margin — (129.68%) 0.00%
Return on equity 359.35% (58.36%) (51.58%)
Return on assets (56.31%) (39.45%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EIKN PRLD Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) (19.15%) 23.21% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric EIKN PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.21 4.20 4.79
Net debt to EBITDA 1.07 1.00 1.01

Dividend

Metric EIKN PRLD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EIKN PRLD Biotechnology median
Market cap 257.93m 260.48m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack